NeuBase Therapeutics Inc
F:O7PA
O7PA's latest stock split occurred on Jun 15, 2023
The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.
The adjusted shares began trading on Jun 15, 2023. This was O7PA's 2nd stock split, following the previous one in Feb 4, 2019.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Feb 17, 2026
|
M
|
Manning Ventures Inc
OTC:MANVF
|
1-for-10
/10
|
0.015 0.15 USD | 0.15 0.15 USD |
|
Feb 17, 2026
|
I
|
Intelligent Group Ltd
NASDAQ:INTJ
|
1-for-20
/20
|
0.334 6.68 USD | 6.7 6.7 USD |
|
Feb 17, 2026
|
M
|
Manning Ventures Inc
CNSX:MANN
|
1-for-10
/10
|
0.015 0.15 CAD | 0.15 0.15 CAD |
|
Feb 17, 2026
|
J
|
Jeffs Brands Ltd
NASDAQ:JFBR
|
1-for-14
/14
|
0.387 5.418 USD | 4.61 4.61 USD |
|
Feb 17, 2026
|
|
Elite Education Group International Ltd
NASDAQ:EEIQ
|
1-for-16
/16
|
0.1799 2.8784 USD | 3.565 3.565 USD |
EEIQ
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
